Familial Hypercholesterolemia

Electronic records data show race, sex, age and comorbidities influence mortality risk for adults with severe hypercholesterolemia and that one in four of these high-risk patients is not prescribed statin therapy.

PHILADELPHIA — A novel single-dose CRISPR base-editing infusion for patients with heterozygous familial hypercholesterolemia and advanced CAD reduced serum PCSK9 and lowered LDL by up to 55% in one patient, a speaker reported.

Decades of data demonstrate the benefits of statin therapy for people at high CV risk, yet many patients — particularly women — are not treated with statins.

The fully monoclonal angiopoietin-like 3 antibody evinacumab conferred sustained, long-term reductions in LDL and other atherogenic lipoproteins among patients with refractory hyperlipidemia, researchers reported.

For patients with familial hypercholesterolemia, overeating was connected to a lower quality of life, underscoring the need for a multidisciplinary approach when it comes to treating patients in this population, according to researchers.

ARLINGTON, Texas — Familial hypercholesterolemia is common, underdiagnosed and undertreated, and one complementary approach to improve its diagnosis could include leveraging the blood donation system, according to a speaker.

The American Society for Preventive Cardiology Congress on CVD Prevention will be held Friday through Sunday and will emphasize inclusiveness by focusing on the “care of one and all” at risk for CVD.

Evinacumab-dgnb was estimated to increase life expectancy an additional 12 years among patients with homozygous familial hypercholesterolemia already on standard-of-care lipid-lowering therapies, researchers reported.